





(51) International Patent Classification ⁶ : A61K 31/135		A1	(11) International Publication Number: WO 98/11884
			(43) International Publication Date: 26 March 1998 (26.03.98)
(21) International Application Number:	PCT/EP97/05039		
(22) International Filing Date:	15 September 1997 (15.09.97)		
(30) Priority Data:	9619757.9	21 September 1996 (21.09.96)	GB
(71) Applicant (for all designated States except US):	KNOLL AKTIENGESELLSCHAFT [DE/DE]; Knollstrasse, D-67061 Ludwigshafen (DE).	(81) Designated States:	AL, AU, BG, BR, BY, CA, CN, CZ, GE, HU, IL, JP, KR, KZ, LT, LV, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TR, UA, US, Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).
(72) Inventors; and		Published	
(75) Inventors/Applicants (for US only):	BAILEY, Clifford, James [GB/GB]; Aston University, Dept. of Pharmaceutical and Biological Sciences, Aston Triangle, Birmingham B4 7ET (GB). JONES, Robert, Brian [GB/GB]; R3 Pennyfoot Street, Nottingham, Nottinghamshire NG1 1GF (GB). JACKSON, Helen, Christine [GB/GB]; R3 Pennyfoot Street, Nottingham, Nottinghamshire NG1 1GF (GB).	With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.	
(74) Agents:	MILLER, Thomas, Kerr et al.; BASF Aktiengesellschaft, D-67056 Ludwigshafen (DE).		

(54) Title: USE OF SIBUTRAMINE ANALOGUES TO PREVENT THE DEVELOPMENT OF DIABETES

Effect of sibutramine on insulin hypoglycaemia in ob/ob mice



(57) Abstract

A compound of formula (I) or a pharmaceutically acceptable salt thereof in which R₁ and R₂ are independently H or methyl (for example *N,N*-dimethyl-1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutyl amine hydrochloride optionally in the form of its monohydrate) is used for reducing Insulin resistance in humans in whom Impaired Glucose Tolerance and Non-Insulin Dependent Diabetes Mellitus have not presented.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

USE OF SIBUTRAMINE ANALOGUES TO PREVENT THE DEVELOPMENT OF DIABETES

This invention relates to a method of reducing insulin resistance in humans in whom Impaired Glucose Tolerance (IGT) and Non-Insulin Dependent Diabetes Mellitus (NIDDM) have not presented.

At present, a person who has a fasting plasma glucose level of greater than 7.8 mmol/l is classified as being diabetic (although this value is currently under review and may soon be set at a lower level, between 6 and 7 mmol/l). However, there is a standard means of classifying whether or not a person is diabetic, and this is important when a person has a fasting blood glucose level just below the above stated level. This means is called the Oral Glucose Tolerance Test (OGTT).

The OGTT is conducted in the following manner. After an overnight fast of 10-16 hours, a fasting blood glucose reading is taken. Glucose (75 g) is administered orally in water (250-300 ml). A further blood glucose reading is taken after 2 hours. Diabetes is diagnosed if the fasting glucose level is greater than 7.8 mmol/l or if the 2 hour level is greater than 11.1 mmol/l. Impaired Glucose Tolerance (IGT) is diagnosed if the fasting glucose level is less than 7.8 mmol/l and the 2 hour value is in the range 7.8-11.1 mmol/l. Normal glucose tolerance is declared if both the fasting glucose level and the 2 hour level are less than 7.8 mmol/l.

The majority of people are non-diabetic and have normal glucose tolerance. A proportion of these people will be at risk of developing Impaired Glucose Tolerance and/or diabetes in the future. One well-documented risk-factor is obesity, in which mild insulin resistance is a common phenomenon. This is often compensated for in the obese body by an increase in the plasma insulin level. However, the body can only increase its insulin secretion to a certain level, so if the insulin resistance continues to worsen in an obese person, eventually the body will not be able to compensate by providing extra insulin. At this time the plasma glucose levels will start to become elevated, presenting IGT or Non-Insulin Dependent Diabetes Mellitus (NIDDM).

Clearly, this gradual decline towards IGT and NIDDM is undesirable both for the individual and in terms of the cost of healthcare. It would, therefore, be advantageous to restrict insulin resistance for as long as possible in these people.


The term "glucose tolerance" includes glucose disposal in muscle tissue, and hepatic glucose output.

The term "Insulin resistance" means a reduced biological response to insulin.

5 Insulin resistance can involve effects on both hepatic glucose output and peripheral glucose uptake, and may be due to reduced insulin receptor numbers, reduced tyrosine kinase activity of the insulin receptor and/or abnormalities distal to the receptor.

Surprisingly, it has now been found that the administration of certain arylcyclobutylalkylamines has efficacy in reducing insulin resistance.

According to the present invention there is provided a method for reducing insulin resistance in humans in whom Impaired Glucose Tolerance or Non-Insulin Dependent Diabetes Mellitus have not presented but in whom there is an increased risk of developing such conditions, said method comprising administering to a human in need thereof a therapeutically effective amount of a compound of formula I



including enantiomers and pharmaceutically acceptable salts thereof, in which R₁ and R₂ are independently H or methyl, in conjunction with a pharmaceutically acceptable diluent or carrier. The human may be obese or may be not obese.

The preparation and use of compounds of formula I, such as *N,N*-dimethyl-1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutylamine (or *N*{1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutyl}-*N,N*-dimethylamine) and salts thereof, in the treatment of depression is described in British Patent Specification 2098602. The use of compounds of formula I such as *N,N*-dimethyl-1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutylamine and salts thereof in the treatment of Parkinson's disease is described in European Patent Number 282206. The use of *N,N*-dimethyl-1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutylamine and salts thereof in the treatment of cerebral function disorders is described in US Patent 4939175. The use of *N,N*-dimethyl-1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutylamine hydrochloride in the

treatment of obesity is described in European Patent Number 397831. A particularly preferred form of this compound is *N,N*-dimethyl-1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutylamine hydrochloride monohydrate (sibutramine hydrochloride monohydrate) which is described in European Patent Number 230742. The use of 5 *N,N*-dimethyl-1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutylamine and salts thereof for improving the glucose tolerance of humans having Impaired Glucose Tolerance or Non-Insulin Dependent Diabetes Mellitus is described in published PCT application WO95/20949. It does not disclose or suggest that the compounds of the present invention possess an insulin sensitising activity, nor does it disclose or suggest that the 10 compounds of the present invention would be able to reduce insulin resistance in humans in whom IGT and NIDDM have not presented.

It may be appreciated by those skilled in the art that compounds of formula I may exist as salts with pharmaceutically acceptable acids. Examples of such salts 15 include hydrochlorides, hydrobromides, sulphates, methanesulphonates, nitrates, maleates, acetates, citrates, fumarates, tartrates [eg (+)-tartrates, (-)-tartrates or mixtures thereof including racemic mixtures], succinates, benzoates and salts with amino acids such as glutamic acid. Compounds of formula I and their salts may exist 20 in the form of solvates (for example hydrates).

It will be appreciated by those skilled in the art that compounds of formula I 25 contain a chiral centre. When a compound of formula I contains a single chiral centre it may exist in two enantiomeric forms. The present invention includes the use of the individual enantiomers and mixtures of the enantiomers. The enantiomers may be resolved by methods known to those skilled in the art, for example by formation of diastereoisomeric salts or complexes which may be separated, for example, by crystallisation; via formation of diastereoisomeric derivatives which may be separated, for example, by crystallisation, gas-liquid or liquid chromatography; selective reaction 30 of one enantiomer with an enantiomer-specific reagent, for example enzymatic oxidation or reduction, followed by separation of the modified and unmodified enantiomers; or gas-liquid or liquid chromatography in a chiral environment, for example on a chiral support, for example silica with a bound chiral ligand or in the presence of a chiral solvent. It will be appreciated that where the desired enantiomer 35 is converted into another chemical entity by one of the separation procedures described above, a further step is required to liberate the desired enantiomeric form. Alternatively, specific enantiomers may be synthesised by asymmetric synthesis using

optically active reagents, substrates, catalysts or solvents, or by converting one enantiomer to the other by asymmetric transformation.

Specific compounds of formula I are *N,N*-dimethyl-1-[1-(4-chlorophenyl)-5 cyclobutyl]-3-methylbutylamine, *N*-(1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutyl)-*N*-methylamine, and 1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutylamine including racemates, individual enantiomers and mixtures thereof, and pharmaceutically acceptable salts thereof. A preferred compound of formula I is *N,N*-dimethyl-1-[1-(4-chlorophenyl)- cyclobutyl]-3-methylbutylamine or a salt thereof, for example the 10 hydrochloride salt. A preferred form of this hydrochloride is its monohydrate.

The compound of formula I may be administered in any of the known pharmaceutical dosage forms. The amount of the compound to be administered will depend on a number of factors including the age of the patient, the severity of the 15 condition and the past medical history of the patient and always lies within the sound discretion of the administering physician but it is generally envisaged that the dosage of the compound to be administered will be in the range 0.1 to 50 mg preferably 1 to 30 mg per day given in one or more doses.

Oral dosage forms are the preferred compositions for use in the present 20 invention and these are the known pharmaceutical forms for such administration, for example tablets, capsules, granules, syrups and aqueous or oil suspensions. The excipients used in the preparation of these compositions are the excipients known in the pharmacist's art. Tablets may be prepared from a mixture of the active compound 25 with fillers, for example calcium phosphate; disintegrating agents, for example maize starch; lubricating agents, for example magnesium stearate; binders, for example microcrystalline cellulose or polyvinylpyrrolidone and other optional ingredients known in the art to permit tableting the mixture by known methods. The tablets may, if desired, be coated using known methods and excipients which may include enteric 30 coating using for example hydroxypropylmethylcellulose phthalate. The tablets may be formulated in a manner known to those skilled in the art so as to give a sustained release of the compounds of the present invention. Such tablets may, if desired, be provided with enteric coatings by known methods, for example by the use of cellulose acetate phthalate. Similarly, capsules, for example hard or soft gelatin capsules, 35 containing the active compound with or without added excipients, may be prepared by known methods and, if desired, provided with enteric coatings in a known manner.

The contents of the capsule may be formulated using known methods so as to give sustained release of the active compound. The tablets and capsules may conveniently each contain 1 to 50 mg of the active compound.

5 Other dosage forms for oral administration include, for example, aqueous suspensions containing the active compound in an aqueous medium in the presence of a non-toxic suspending agent such as sodium carboxy-methylcellulose, and oily suspensions containing a compound of the present invention in a suitable vegetable oil, for example arachis oil. The active compound may be formulated into granules
10 with or without additional excipients. The granules may be ingested directly by the patient or they may be added to a suitable liquid carrier (for example, water) before ingestion. The granules may contain disintegrants, eg an effervescent couple formed from an acid and a carbonate or bicarbonate salt to facilitate dispersion in the liquid medium.

15 The therapeutically active compounds of formula I may be formulated into a composition which the patient retains in his mouth so that the active compound is administered through the mucosa of the mouth.

20 Dosage forms suitable for rectal administration are the known pharmaceutical forms for such administration, for example, suppositories with cocoa butter or polyethylene glycol bases.

25 Dosage forms suitable for parenteral administration are the known pharmaceutical forms for such administration, for example sterile suspensions or sterile solutions in a suitable solvent.

30 Dosage forms for topical administration may comprise a matrix in which the pharmacologically active compounds of the present invention are dispersed so that the compounds are held in contact with the skin in order to administer the compounds transdermally. A suitable transdermal composition may be prepared by mixing the pharmaceutically active compound with a topical vehicle, such as a mineral oil, petrolatum and/or a wax, e.g. paraffin wax or beeswax, together with a potential transdermal accelerator such as dimethyl sulphoxide or propylene glycol. Alternatively
35 the active compounds may be dispersed in a pharmaceutically acceptable cream, gel or ointment base. The amount of active compound contained in a topical formulation

should be such that a therapeutically effective amount of the compound is delivered during the period of time for which the topical formulation is intended to be on the skin.

The therapeutically active compound of formula I may be formulated into a
5 composition which is dispersed as an aerosol into the patients oral or nasal cavity. Such aerosols may be administered from a pump pack or from a pressurised pack containing a volatile propellant.

The therapeutically active compounds of formula I used in the method of the
10 present invention may also be administered by continuous infusion either from an external source, for example by intravenous infusion or from a source of the compound placed within the body. Internal sources include implanted reservoirs containing the compound to be infused which is continuously released for example by osmosis and implants which may be (a) liquid such as an oily suspension of the
15 compound to be infused for example in the form of a very sparingly water-soluble derivative such as a dodecanoate salt or a lipophilic ester or (b) solid in the form of an implanted support, for example of a synthetic resin or waxy material, for the compound to be infused. The support may be a single body containing all the compound or a series of several bodies each containing part of the compound to be delivered. The
20 amount of active compound present in an internal source should be such that a therapeutically effective amount of the compound is delivered over a long period of time.

In some formulations it may be beneficial to use the compounds of the present
25 invention in the form of particles of very small size, for example as obtained by fluid energy milling.

In the compositions of the present invention the active compound may, if desired, be associated with other compatible pharmacologically active ingredients.

30 The following *in vitro* and *in vivo* tests support the finding that compounds of formula I have efficacy in reducing insulin resistance, and may have an insulin sensitising action. It will be appreciated by those skilled in the art that 10 mg of sibutramine in the form of the hydrochloride monohydrate is equivalent to 8.37 mg of
35 sibutramine as free base.

Study 1 In vitro L6 muscle cells

L6 Muscle cells were obtained from the European Culture Collection (Porton Down) and were used at passages 7-11. Cells were maintained in standard tissue culture medium DMEM, and glucose uptake was assessed using [³H]-2-deoxyglucose (2DG) with and without the presence of added insulin (10⁻⁸ M) as has been previously described (Walker PS et al, Glucose transport activity in L6 muscle cells is regulated by the coordinate control of subcellular glucose transporter distribution, biosynthesis, and mRNA transcription, JBC, 1990;265(3),1516-1523, and Kilp A et al, Stimulation of hexose transport by metformin in L6 muscle cells in culture, Endocrinology,1992;130(5), 2535-2544).

Uptake of 2DG was expressed as the percentage change compared with control. Values are presented as mean \pm SEM of sets of 4 wells per experiment. Differences between sets of wells were evaluated by Student's t test, probability values p<0.05 were considered to be significant. In the absence of added insulin, L6 cells incubated for 24 hours with the compound of formula I in which R₁ and R₂ are both H, showed a significant increase in 2DG uptake (from 100 \pm 2.1 in controls to 116.9 \pm 3.8, 123.9 \pm 4.3 and 134 \pm 7.3 at 10⁻⁸, 10⁻⁷ and 10⁻⁶ M respectively). In the presence of added insulin (10⁻⁸ M), significant increases in 2DG uptake were observed following 24 hour incubation with the compound of formula I in which R₁ and R₂ are both methyl (sibutramine hydrochloride monohydrate) at 10⁻⁸ M (from 149.9 \pm 4.3 to 165.3 \pm 2.6), the compound of formula I in which R₁ is methyl and R₂ is H at 10⁻⁷ M (from 147.3 \pm 3.0 to 160.7 \pm 4.5), and the compound of formula I in which R₁ and R₂ are both H, at 10⁻⁷ M and 10⁻⁶ M (from 149.1 \pm 3.9 to 161.8 \pm 3.3 and 165.2 \pm 3.6 respectively).

This study shows that in the presence or absence of added insulin, compounds of formula I increase glucose uptake in L6 muscle cells.

Study 2 - In vivo ob/ob mice

Studies were performed in obese *ob/ob* mice (Aston Strain) which are a model of severe insulin resistance and are also hyperglycaemic. The derivation and

characteristics of this animal model have been previously described (Flatt PR, Bailey CJ, Development of glucose intolerance and impaired plasma insulin response to glucose in obese hyperglycaemic (*ob/ob*) mice, Horm Metab Res 1981;13:556-560, and Bailey CJ et al, Influence of genetic background and age on the expression of 5 the obese hyperglycaemic syndrome in Aston *ob/ob* mice, Int J Obesity, 1982;6:11-21).

The *ob/ob* mice were individually housed in polypropylene cages at a temperature of $21\pm1^{\circ}\text{C}$ and 55% humidity. The mice had free access to a standard 10 rat and mouse pelleted diet (Compound Rat and Mouse Diet, Special Diet Services, Witham, Essex) and tap water at all times. Animals were maintained on a reverse phase light-dark cycle. Lights were off between 09.00 h and 17.00 h in the acute experiment and between 10.00 h and 18.00 h in the chronic experiment. During this time the laboratory was illuminated by red lamps. Animals were acclimatised to 15 these conditions for at least two weeks before experimentation.

All animals were given deionised water (at the start of the dark period) for 7 days. Body weight and food intake were measured daily. Blood samples were taken immediately before daily administration of vehicle (deionised water 10ml/kg 20 po) or compound of formula I in which R_1 and R_2 are both methyl (sibutramine hydrochloride monohydrate; 10 mg/kg po) on day 1 (baseline) and after 14 and 28 days of treatment (on day 15 and day 29 respectively). Blood samples were also taken 14 days following withdrawal of the sibutramine hydrochloride monohydrate 25 (on day 43 of the study). Plasma glucose was determined by a glucose oxidase procedure (Analox GM7) and plasma insulin determined by radioimmunoassay (Amerlex, Amersham).

No significant changes in body weight or food intake were observed between 30 vehicle and sibutramine hydrochloride monohydrate. Plasma glucose in sibutramine hydrochloride monohydrate-treated *ob/ob* fell after 14 and 28 days of treatment, with a significant difference from control at day 28 ($P<0.01$, Table 1). After 14 days of drug withdrawal, plasma glucose was unaffected in the vehicle dosed group but rose significantly in the sibutramine hydrochloride monohydrate treated group to control 35 values. No significant changes in plasma insulin were observed though plasma insulin tended to fall in the sibutramine hydrochloride monohydrate treated group and increased on compound withdrawal.

Study 3 - In vivo ob/ob mice

Young ob/ob mice (Aston Strain) were randomised into 3 groups as follows:

5 control, receiving placebo treatment (phosphate buffered saline 2.5 ml/kg/day po); sibutramine hydrochloride monohydrate-treated (5 mg/kg/day po); and pair-fed control, supplied with the same daily food intake as that consumed by the sibutramine hydrochloride monohydrate-treated group on the previous day. There was a 1 week run-in period followed by 6 weeks of treatment. Body weight and food
10 intake were monitored every 1 to 2 days, and blood samples for plasma glucose and insulin were taken from the tail vein at weekly intervals in the non-fasted state at 11 a.m. An ip glucose tolerance test (D-glucose, 2 g/kg in 40% w/v solution in distilled water) and an insulin hypoglycaemia test (Actrapid, Novo-Nordisk, 2.5 u/kg ip) were conducted after 5 weeks of treatment. Food was withheld only for the duration of
15 these tests (approx. 4 hours). The basal blood samples and the test procedures were undertaken 18 hours after the last treatment administration.

Treatment was stopped after 6 weeks, and the mice were monitored for the next 6 weeks. The pair-fed mice continued to be pair-fed with respect to the
20 sibutramine hydrochloride monohydrate withdrawal group. A second insulin hypoglycaemia test was conducted 4 weeks after treatment was stopped. Plasma glucose was determined by an automated glucose oxidase procedure (Beckman) and plasma insulin determined by radioimmunoassay (Amerlex, Amersham).

25 During sibutramine hydrochloride monohydrate treatment, significant reduction in body weight and plasma insulin compared to vehicle were observed. In an ip glucose tolerance test significant reductions in plasma insulin ($P<0.05$; see Figure 1) and in plasma glucose ($P<0.05$; see Figure 2) were observed with sibutramine hydrochloride monohydrate treatment compared to the vehicle treated
30 group. Significant improvements in insulin hypoglycaemia ($P<0.05$; see Figure 3; at 5 weeks) with sibutramine hydrochloride monohydrate treatment compared to the vehicle treated group were also observed. These results indicate that compounds of formula I, at a relatively low dose, are able to provide an improvement in insulin sensitivity because there is better glucose utilisation with less insulin. The pair-fed
35 group showed a similar weight reduction to the sibutramine hydrochloride monohydrate treated group, but no improvement was observed in the oral glucose

10

tolerance test. Therefore the pair-fed group do not show an improvement in insulin sensitivity.

During the sibutramine hydrochloride monohydrate withdrawal period, body
5 weight and plasma insulin remained significantly lower than the vehicle treated group
for almost all of the 6 week withdrawal period.

In Table 1 and Figures 1-3, "sibutramine" indicates "sibutramine hydrochloride monohydrate".

10

TABLE 1

Effect of chronic administration of the compound of formula I in which R₁ and R₂ are both methyl (10 mg/kg po) and its withdrawal on plasma glucose and plasma insulin in ob/ob mice.

Treatment	Day of Study	Treatment Days	Vehicle (n)	Plasma glucose (mmol/l)		Vehicle	Compound	Plasma insulin (ng/ml)	Compound
				Compound (n)	Vehicle				
Prior to treatment	1	0	22	32	24.3 ± 0.6	24.3 ± 0.6	92.0 ± 4.5	92.0 ± 4.5	
Sibutramine	15	14	22	32	21.7 ± 0.9	19.0 ± 0.6	49.7 ± 3.5	45.1 ± 2.6	
Sibutramine	29	28	14	21	26.0 ± 1.4	15.8 ± 0.7**	46.2 ± 4.5	35.1 ± 2.7	
Drug Withdrawal	43	14	6	12	22.9 ± 1.7	23.6 ± 1.2	40.6 ± 8.6	77.1 ± 11.3	

Values are back-transformed means ± SEM adjusted for differences between the treatment groups at baseline. Significant differences from the vehicle-treated control group are denoted by **P<0.01. (n) is the number of animals involved.

The data from the three studies indicate that compounds of formula I can enhance both basal and insulin stimulated glucose uptake into the L6 muscle cells and that in the absence of changes in either body weight or food intake, the compound of formula I in which R₁ and R₂ are both methyl can reduce plasma glucose levels in ob/ob mice. These data taken together suggest an insulin sensitising action of compounds of formula I. The data also indicate the ability of compounds of formula I to decrease insulin resistance.

There are several syndromes, such as acanthosis nigricans, leprechaunism, lipoatrophy and polycystic ovary syndrome, which exhibit insulin resistance as part of their profile. The above data suggest that a compound of formula I may have utility in alleviating the insulin resistance in humans having such conditions. Therefore the present invention further provides the use of a compound of formula I in the manufacture of a medicament for reducing insulin resistance in humans having acanthosis nigricans, leprechaunism, lipoatrophy or polycystic ovary syndrome or other conditions in which insulin resistance is present.

The present invention also provides a method of treatment for acanthosis nigricans, leprechaunism, lipoatrophy or polycystic ovary syndrome or other conditions in which insulin resistance is present, comprising administration of a compound of formula I to a patient in need thereof in conjunction with a pharmaceutically acceptable diluent or carrier.

NIDDM patients are often treated with oral insulin secretagogues, such as 1,1-dimethyl-2-(2-morpholinophenyl)guanidine fumarate (BTS67582) or sulfonylureas including tolbutamide, tolazamide, chlorpropamide, glibenclamide, glimepiride, glipizide and gliclazide, or with insulin sensitising agents including metformin, ciglitazone, troglitazone and pioglitazone. A further use of a compound of formula I is in the manufacture of a medicament, for combination therapy of NIDDM patients to improve their weight and diabetic control, comprising a compound of formula I and an oral insulin secretagogue or an insulin sensitising agent.

The present invention further provides a method of improving the weight and diabetic control of NIDDM patients comprising the administration of a compound of formula I in combination with an oral insulin secretagogue or an insulin sensitising agent

in conjunction with a pharmaceutically acceptable diluent or carrier to a human in need thereof.

Preferably, the oral insulin secretagogue is 1,1-dimethyl-2-(2-morpholino phenyl)guanidine fumarate (BTS67582) or a sulphonylurea selected from tolbutamide, tolazamide, chlorpropamide, glibenclamide, glimepiride, glipizide and gliclazide. Preferably, the insulin sensitising agent is selected from metformin, ciglitazone, troglitazone and pioglitazone.


The compound of formula I and the oral insulin secretagogue or insulin sensitising agent may be administered either concomitantly or concurrently, for example in the form of separate dosage units to be used simultaneously, separately or sequentially. Accordingly, the present invention further provides a product containing a compound of formula I and an oral insulin secretagogue or insulin sensitising agent as a combined preparation for simultaneous, separate or sequential use for the improvement of weight and diabetic control in NIDDM patients. The ratio of the compound of formula I to the oral insulin secretagogue or insulin sensitising agent is such that the quantity of each active ingredient employed will be such as to provide a therapeutically effective level, but will not be larger than the quantity recommended as safe for administration.

The action of reducing insulin resistance shown by compounds of formula I indicates that compounds of formula I may be useful in the manufacture of a medicament which can be used as an insulin sensitiser. Accordingly, the present invention further provides the use of a compound of formula I in the manufacture of a medicament which is an insulin sensitiser.

Some patients who are diagnosed as being Insulin Dependent Diabetics can also show a certain amount of insulin resistance. Therefore, there may be benefits in treating these patients with a compound of formula I in order to reduce their insulin resistance. This would mean that these patients would require a lower dosage of insulin in order to maintain similar or better control of their diabetes since the insulin dose would be associated with a greater blood glucose lowering efficacy. Such therapy would provide long-term benefits in terms of reducing the detrimental effects which can be caused by prolonged high-dosage of insulin treatment. Additionally, some NIDDM patients are also treated with insulin and have insulin resistance. Accordingly the


present invention further provides a method for, and the use of a compound of formula I in the manufacture of the medicament for, reducing the amount of insulin required daily by a human having Insulin Dependent Diabetes Mellitus or NIDDM. The present invention also provides a method for, and the use of a compound of formula I in the manufacture of a medicament for, the prophylaxis of long-term detrimental effects caused by prolonged high dosage of insulin in humans having Insulin Dependent Diabetes Mellitus or NIDDM.

1. A method of reducing insulin resistance in humans in whom Impaired Glucose Tolerance or Non-Insulin Dependent Diabetes Mellitus have not presented but in whom there is an increased risk of developing such conditions, said method comprising administering to a human in need thereof a therapeutically effective amount of a compound of formula I



including enantiomers and pharmaceutically acceptable salts thereof in which R₁ and R₂ are independently H or methyl, in conjunction with a pharmaceutically acceptable diluent or carrier.


2. A method as claimed in claim 1 in which the human is not obese.
3. A method as claimed in claim 1 in which the human is obese.
4. A method as claimed in any preceding claim wherein the compound of formula I is *N,N*-dimethyl-1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutylamine hydrochloride.
5. A method as claimed in any preceding claim wherein the compound of formula I is *N,N*-dimethyl-1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutylamine hydrochloride in the form of its monohydrate.
6. Use of a compound of formula I



including enantiomers and pharmaceutically acceptable salts thereof in which R₁ and R₂ are independently H or methyl, in the manufacture of a medicament for reducing insulin

resistance in humans in whom Impaired Glucose Tolerance and Non-Insulin Dependent Diabetes Mellitus have not presented but in whom there is an increased risk of developing such conditions.

7. The use as claimed in claim 6 in which the human is not obese.
8. The use as claimed in claim 6 in which the human is obese.
9. The use as claimed in claim 6,7 or 8 in which the compound of formula I is *N,N*-dimethyl-1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutylamine hydrochloride.
10. The use as claimed in claim 6,7 or 8 in which the compound of formula I is *N,N*-dimethyl-1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutylamine hydrochloride monohydrate.
11. A pharmaceutical composition for reducing insulin resistance in humans in whom Impaired Glucose Tolerance and Non-Insulin Dependent Diabetes Mellitus have not presented but in whom there is an increased risk of developing such conditions, comprising a therapeutically effective amount of a compound of formula I



including enantiomers and pharmaceutically acceptable salts thereof in which R₁ and R₂ are independently H or methyl, in conjunction with a pharmaceutically acceptable diluent or carrier.

12. A pharmaceutical composition as claimed in claim 11 in which the compound of formula I is *N,N*-dimethyl-1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutylamine hydrochloride.

13. A pharmaceutical composition as claimed in claim 11 in which the compound of formula I is *N,N*-dimethyl-1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutylamine hydrochloride monohydrate.

14. Use of a compound of formula I in the manufacture of a medicament which is an insulin sensitiser.
15. Use of a compound of formula I in the manufacture of a medicament for reducing the amount of insulin required daily by a human having Insulin Dependent Diabetes Mellitus or NIDDM.
16. Use of a compound of formula I in the manufacture of a medicament for the prophylaxis of long-term detrimental effects caused by prolonged high doses of insulin in humans having Insulin Dependent Diabetes Mellitus or NIDDM.
17. Use of a compound of formula I in the manufacture of a medicament for the prophylaxis of Impaired Glucose Tolerance and Non-insulin Dependent Diabetes Mellitus in humans having a high risk of developing the same.
18. Use as claimed in claim 17 in which the human is not obese.
19. Use of a compound for formula I in the manufacture of a medicament for reducing insulin resistance in humans having acanthosis nigricans, leprechaunism, lipoatrophy or polycystic ovary syndrome or other conditions in which insulin resistance is present.
20. Use of a compound of formula I in the manufacture of a medicament for combination therapy of NIDDM patients to improve their weight and diabetic control, comprising a compound of formula I and an oral insulin secretagogue or insulin sensitising agent.
21. A method of improving the weight and diabetic control of NIDDM patients comprising the administration of a compound of formula I in combination with an oral insulin secretagogue or insulin sensitising agent in conjunction with a pharmaceutically acceptable diluent or carrier to a human in need thereof.

22. A product containing a compound of formula I and an oral insulin secretagogue or insulin sensitising agent as a combined preparation for simultaneous, separate or sequential use for the improvement of weight and diabetic control in NIDDM patients.
23. A product comprising a pharmaceutical composition which comprises a compound of formula I and an oral insulin secretagogue or insulin sensitising agent together with a pharmaceutically acceptable diluent or carrier.
24. A product as claimed in claim 22 or 23 in which the oral insulin secretagogue is 1,1-dimethyl-2-(2-morpholinophenyl)guanidine fumarate (BTS67582) or a sulfonylurea selected from tolbutamide, tolazamide, chlorpropamide, glibenclamide, glimepiride, glipizide and gliclazide.
25. A product as claimed in claim 22 or 23 in which the insulin sensitising agent is selected from metformin, ciglitazone, troglitazone and pioglitazone.
26. A method for reducing the amount of insulin required daily by a human having Insulin Dependent Diabetes Mellitus or NIDDM comprising the administration of a compound of formula I in conjunction with a pharmaceutically acceptable diluent or carrier to a human in need thereof.
27. A method for the prophylaxis of long-term detrimental effects caused by prolonged high doses of insulin in humans having Insulin Dependent Diabetes Mellitus or NIDDM comprising the administration of a compound of formula I in conjunction with a pharmaceutically acceptable diluent or carrier to a human in need thereof.
28. A method for the prophylaxis of Impaired Glucose Tolerance and Non-Insulin Dependent Diabetes Mellitus in humans having a high risk of developing the same comprising the administration of a compound of formula I in conjunction with a pharmaceutically acceptable diluent or carrier to a human in need thereof.
29. A method as claimed in claim 27 in which the human is not obese.
30. A method of reducing insulin resistance in humans having acanthosis nigricans, leprechaunism, lipoatrophy or polycystic ovary syndrome or other conditions in which insulin resistance is present comprising the administration of a compound of formula I in

conjunction with a pharmaceutically acceptable diluent or carrier to a human in need thereof.

1/3


FIGURE 1**Effect of sibutramine on plasma insulin in GTT in ob/ob mice**

FIGURE 2

Effect of sibutramine on plasma glucose in GTT in ob/ob mice





FIGURE 3

Effect of sibutramine on insulin hypoglycaemia in ob/ob mice



INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP 97/05039

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 A61K31/135

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	<p>R.B. JONES ET AL.: "Chronic administration of sibutramine reduces plasma glucose levels in obese hyperglycemic (ob/ob) mice." BR. J. PHARMACOL., vol. 120, no. supplement, 1997, page 352P XP002054666 see the whole document</p> <p>---</p> <p>M.E.J. LEAN: "Sibutramine-a review of clinical efficacy." INT. J. OBES. RELAT. METAB. DISORD., vol. 21, no. supplement 1, 1997, pages S30-S36, XP002054667 see the whole document</p> <p>---</p> <p>---</p>	1,3,4,6, 8,9,11, 12,14,17
P, X		1,3,4,6, 8,9,11, 12,14,17

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

1

Date of the actual completion of the international search

5 February 1998

Date of mailing of the international search report

20/02/1998

Name and mailing address of the ISA

European Patent Office, P. B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.
Fax: (+31-70) 340-3016

Authorized officer

Klaver, T

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 97/05039

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication where appropriate, of the relevant passages	Relevant to claim No.
X	R. VARGAS ET AL.: "Effects of sibutramine vs placebo in NIDDM" CLIN. PHARMACOL. THERAP., vol. 55, no. 2, 1994, page 188 XP002054668 abstract PIII-24 see the whole document ----	1,3,4,6, 8,9,11, 12,14,17
X	WO 95 20949 A (BOOTS PHARMACEUTICALS) 10 August 1995 cited in the application see the whole document -----	1,3,4,6, 8,9,11, 12,14,17

INTERNATIONAL SEARCH REPORT

Information on patent family members

Internatio	Application No
PCT/EP 97/05039	

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9520949 A	10-08-95	US 5459164 A AU 1736295 A CA 2182620 A CN 1144479 A EP 0814788 A ZA 9500814 A	17-10-95 21-08-95 10-08-95 05-03-97 07-01-98 03-08-95